Demystifying immunotherapy in prostate cancer: Understanding current and future treatment strategies

Cancer Journal (United States)

Volumn 19, Issue 1, 2013, Pages 50-58

  Madan, Ravi A ^a   Gulley, James L ^a   Kantoff, Philip W ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

combination immunotherapy; immune checkpoint inhibitors; Immunotherapy; prostate cancer; therapeutic cancer vaccines

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; INTERCELLULAR ADHESION MOLECULE 1; IPILIMUMAB; PLACEBO; PROGRAMMED DEATH 1 LIGAND ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR; PROSTATE SPECIFIC ANTIGEN; PROTEIN ANTIBODY; PSA TRICOM VACCINE; SIPULEUCEL T; SMALLPOX VACCINE; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL TRIAL (TOPIC); COLITIS; CYTOTOXIC T LYMPHOCYTE; DERMATITIS; DRUG EFFICACY; DRUG SAFETY; EX VIVO STUDY; FEVER; FOOD AND DRUG ADMINISTRATION; HAZARD RATIO; HUMAN; HYPOTHESIS; IMMUNOREGULATION; INJECTION SITE REACTION; LEUKAPHERESIS; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PANHYPOPHYSITIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE PRICING; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIATION DOSE; RECEPTOR UPREGULATION; REVIEW; T LYMPHOCYTE; THYROIDITIS; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR VOLUME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CANCER VACCINES; COMBINED MODALITY THERAPY; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; MALE; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84873854314     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e31828160a9     Document Type: Review

References (88)

1. Bostwick DG, Pacelli A, Blute M, et al. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocar-cinoma: a study of 184 cases. Cancer. 1998;82:2256-2261.
2. Goldfarb DA, Stein BS, Shamszadeh M, et al. Age-related changes in tissue levels of prostatic acid phosphatase and prostate specific antigen. J Urol. 1986;136:1266-1269.
3. Wang MC, Valenzuela LA, Murphy GP, et al. Purification of a human prostate specific antigen. Invest Urol. 1979;17:159-163.
4. Chakraborty NG, Stevens RL, Mehrotra S, et al. Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation. Cancer Immunol Immunother. 2003;52: 497-505.
5. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294:238-244.
6. Di Lorenzo G, Ferro M, Buonerba C. Sipuleucel-T (Provenge(R)) for castration-resistant prostate cancer. BJU Int. 2012;110:E99-E104.
7. Madan RA, Arlen PM, Mohebtash M, et al. PROSTVAC-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs. 2009;18:1001-1011.
8. Small EJ, Sacks N, Nemunaitis J, et al. Granulocyte macrophage colony-stimulating factorYsecreting allogeneic cellular immuno-therapy for hormone-refractory prostate cancer. Clin Cancer Res. 2007;13:3883-3891.
9. Patel PH, Kockler DR. Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer. Ann Pharmacother. 2008;42:91-98.
10. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995;182:459-465.
11. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science. 1995;270:985-988.
12. Pardoll D. Releasing the brakes on antitumor immune response. Science. 1996;271:1691.
13. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmu-nity induced by cytotoxic T lymphocyteYassociated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA. 2003; 100:8372-8377.
14. Weber JS, O'Day S, Urba W, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol. 2008;26:5950-5956.
15. Ascierto PA, Simeone E, Sznol M, et al. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol. 2010;37:508-516.
16. Rini BI. Technology evaluation: APC-8015, Dendreon. Curr Opin Mol Ther. 2002;4:76-79.
17. Sheikh NA, Petrylak D, Kantoff PW, et al. Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer [published online ahead of print August 3, 2012]. Cancer Immunol Immunother. 2012.
18. Burch PA, Breen JK, Buckner JC, et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res. 2000;6:2175-2182.
19. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol. 2000;18:3894-3903.
20. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006;24:3089-3094.
21. Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;115:3670-3679.
22. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411-422.
23. FDA Approval for Sipuleucel-T. Available at: http://www.cancer.gov/ cancertopics/druginfo/fda-sipuleucel-T. Accessed October 21, 2012.
24. Beer TM, Bernstein GT, Corman JM, et al. Randomized trial of autolo-gous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Clin Cancer Res. 2011;17:4558-4567.
25. Sipuleucel-T as Neoadjuvant Treatment in Prostate Cancer (NeoACT). Available at: http://clinicaltrials.gov/show/NCT00715104. Accessed October 21, 2012.
26. Huber ML, Haynes L, Parker C, et al. Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst. 2012;104:273-279.
27. Kantoff PW, Higano CS, Small EJ, et al. Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst. 2012;104:1107-1109; author reply 9-12.
28. Gulley JL, Leitman SF, Dahut W, et al. Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst. 2012;104:1106; author reply 9-12.
29. Drake CG. Re: interdisciplinary critique of sipuleucel-T as immuno-therapy in castration-resistant prostate cancer. J Natl Cancer Inst. 2012;104:1422; author reply-3.
30. Longo DL. New therapies for castration-resistant prostate cancer. N Engl J Med. 2010;363:479-481.
31. Essajee S, Kaufman HL. Poxvirus vaccines for cancer and HIV therapy. Expert Opin Biol Ther. 2004;4:575-588.
32. Hodge JW, Chakraborty M, Kudo-Saito C, et al. Multiple costimulatory modalities enhance CTL avidity. J Immunol. 2005;174:5994-6004.
33. Arlen PM, Skarupa L, Pazdur M, et al. Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol. 2007;178:1515-1520.
34. Eder JP, Kantoff PW, Roper K, et al. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res. 2000;6:1632-1638.
35. Marshall JL, Hoyer RJ, Toomey MA, et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol. 2000;18:3964-3973.
36. Gulley J, Chen AP, Dahut W, et al. Phase I study of a vaccine using re-combinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate. 2002;53: 109-117.
37. Kaufman HL, Wang W, Manola J, et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2004;22:2122-2132.
38. Kim JW, Gulley JL. Poxviral vectors for cancer immunotherapy. Expert Opin Biol Ther. 2012;12:463-478.
39. Gulley JL, Arlen PM, Madan RA, et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother. 2010;59:663-674.
40. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28:1099-1105.
41. A Phase 3 Efficacy Study of a Recombinant Vaccinia Virus Vaccine to Treat Metastatic Prostate Cancer (Prospect). Available at: http://www. clinicaltrials.gov/ct2/show/NCT01322490. Accessed October 10, 2012.
42. FDA approves new treatment for a type of late-stage skin cancer. Available at: http://www.fda.gov/newsevents/newsroom/pressannouncements/ ucm1193237.htm. Accessed October 1, 2012.
43. Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007;30:825-830.
44. Madan RA, Mohebtash M, Arlen PM, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13:501-508.
45. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipili-mumab in patients with metastatic melanoma. N Engl J Med. 2010;363: 711-723.
46. Small EJ, Tchekmedyian NS, Rini BI, et al. A pilot trial of CTLA-4 blockade with human antiYCTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res. 2007;13:1810-1815.
47. Garnett CT, Palena C, Chakraborty M, et al. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res. 2004;64:7985-7994.
48. Slovin SF, Hamid O, Tejwani S, et al. Ipilimumab in metastatic castrate-resistant prostate cancer: results from an open-label, multicenter phase I/II study. J Clin Oncol. 2012;30(S5):abstract 25.
49. Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01057810. Accessed October 1, 2012.
50. Study of Immunotherapy to Treat Advanced Prostate Cancer. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00861614. Accessed October 1, 2012.
51. Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11:141-151.
52. Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardio-myopathy in PD-1 receptorYdeficient mice. Science. 2001;291:319-322.
53. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167-3175.
54. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of antiYPD-1 antibody in cancer. N Engl J Med. 2012;366: 2443-2454.
55. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of antiY PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455-2465.
56. Gulley JL, Arlen PM, Bastian A, et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res. 2005;11:3353-3362.
57. Becker JT, Olson BM, Johnson LE, et al. DNA vaccine encoding pros-tatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. J Immunother. 2010;33:639-647.
58. Salazar LG, Coveler AL, Swensen RE, et al. Kinetics of tumor-specific T-cell response development after active immunization in patients with HER-2/neu overexpressing cancers. Clin Immunol. 2007;125:275-280.
59. Levin ML, Wyatt KD. Prospective analysis of laser photophacofrag- mentation. J Cataract Refract Surg. 1990;16:96-98.
60. Disis ML, Wallace DR, Gooley TA, et al. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol. 2009;27:4685-4692.
61. Nesslinger NJ, Ng A, Tsang KY, et al. A viral vaccine encoding prostate-specific antigen induces antigen spreading to a common set of self-proteins in prostate cancer patients. Clin Cancer Res. 2010; 16:4046-4056.
62. Disis ML, Goodell V, Schiffman K, et al. Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients. J Clin Immunol. 2004;24:571-578.
63. Madan RA, Mohebtash M, Schlom J, et al. Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design. Expert Opin Biol Ther. 2010;10:19-28.
64. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148-1159.
65. Hoos A, Eggermont AM, Janetzki S, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst. 2010;102:1388-1397.
66. Butterfield LH, Comin-Anduix B, Vujanovic L, et al. Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J Immunother. 2008;31:294-309.
67. Vergati M, Cereda V, Madan RA, et al. Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre-versus post-vaccination. Cancer Immunol Immunother. 2011;60:197-206.
68. Madan RA, Gulley JL, Fojo T, et al. Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist. 2010;15:969-975.
69. Stein WD, Gulley JL, Schlom J, et al. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res. 2011;17:907-917.
70. Stein WD, Figg WD, Dahut W, et al. Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data. Oncologist. 2008;13:1046-1054.
71. Stein WD, Yang J, Bates SE, et al. Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage. Oncologist. 2008;13:1055-1062.
72. Madan RA, Bilusic M, Heery C, et al. Clinical evaluation of TRICOM vector therapeutic cancer vaccines. Semin Oncol. 2012;39:296-304.
73. Chakraborty DiPaola R, Chen Y, Bubley G, et al. A phase II study of PROSTVAC-V (vaccinia)/TRICOM and PROSTVAC-F (fowlpox)/TRICOM with GM-CSF in patients with PSA progression after local therapy for prostate cancer: results of ECOG 9802 [poster]. Presented at the ASCO Genitourinary Cancers Symposium, Orlando, FL, February 26-28, 2009. Abstract 108.
74. Chakraborty M, Abrams SI, Coleman CN, et al. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res. 2004;64:4328-4337.
75. Chakraborty M, Abrams SI, Camphausen K, et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol. 2003;170:6338-6347.
76. Tesniere A, Panaretakis T, Kepp O, et al. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ. 2008;15:3-12.
77. Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366:925-931.
78. Aragon-Ching JB, Williams KM, Gulley JL. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci. 2007;12:4957-4971.
79. Mercader M, Bodner BK, Moser MT, et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci USA. 2001;98:14565-14570.
80. Heng TS, Goldberg GL, Gray DH, et al. Effects of castration on thy-mocyte development in two different models of thymic involution. J Immunol. 2005;175:2982-2993.
81. Drake CG, Doody AD, Mihalyo MA, et al. Androgen ablation mitigates tolerance to a prostate/prostate cancerYrestricted antigen. Cancer Cell. 2005;7:239-249.
82. Bilusic M, Gulley J, Heery C, et al. A randomized phase II study of flutamide with or without PSA-TRICOM in nonmetastatic castration-resistant prostate cancer. J Clin Oncol. 2011;29(S7). Abstract 163.
83. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367: 1187-1197.
84. L-BLP25 (Stimuvax) in Prostate Cancer. Available at: http://www. clinicaltrials.gov/ct2/show/NCT01496131. Accessed October 21, 2012.
85. Boehm AL, Higgins J, Franzusoff A, et al. Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations. Cancer Immunol Immunother. 2010;59:397-408.
86. van den Eertwegh AJ, Versluis J, van den Berg HP, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13:509-517.
87. Heery C, Ibrahim N, Madan RA, et al. A phase 2 randomized trial of docetaxel alone or in combination with the therapeutic cancer vaccine, CEAYMUC-1YTRICOM. Presented at the 37th Congress of the European Society of Medical Oncology, Vienna, Austria, September 28-October 2, 2012. Abstract LBA14.
88. Heery C, Madan RA, Bilusic M, et al. Interim analysis of a phase II randomized clinical trial of samrium-153 with or without PSA-TRICOM vaccine in metastatic castration-resistant prostate cancer after docetaxel. J Clin Oncol. 2012;30. Abstract 2526.